Coya Therapeutics Completes Patient Enrollment in Frontotemporal Dementia Study

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company developing biologics that enhance regulatory T cell (Treg) function in neurodegenerative disorders, announced the completion of patient enrollment in an investigator-initiated, proof-of-concept, open-label study evaluating a combination of low-dose IL-2 and CTLA4-Ig in patients with Frontotemporal Dementia (FTD).

The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute (Houston, TX) and funded by The Peggy and Gary Edwards Endowment Fund. Participants received subcutaneous CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up.

Following positive interim results from 5 patients reported in April 2025, the study enrolled an additional 4 patients, bringing the total to 9 FTD patients. The trial is proceeding according to protocol, with no serious adverse events or discontinuations due to safety issues. Study completion is anticipated in Q4 2025, with topline results to follow.

Dr. Fred Grossman, CMO of Coya, commented:

"We are pleased to announce the completion of this important clinical milestone. FTD is a devastating neurodegenerative disease with high unmet need. We remain committed to developing an effective and safe treatment for this rare form of dementia."

About Frontotemporal Dementia

Frontotemporal dementia (FTD) encompasses neurodegenerative disorders marked by behavioral changes and language impairment, with progressive decline in executive function. FTD affects an estimated 30,000 Americans and can manifest between ages 45–64, with an average onset at 58 and survival of 7.5 years. Major subtypes include behavioral-variant FTD, semantic dementia, and progressive non-fluent aphasia.

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics is a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) to address systemic inflammation and neuroinflammation. Dysfunctional Tregs contribute to neurodegenerative, metabolic, and autoimmune diseases.

Coya’s pipeline leverages multiple modalities, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, aimed at restoring anti-inflammatory and immunomodulatory functions.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!